Revista chilena de pediatría
versión impresa ISSN 0370-4106
MARTINEZ M., José Luis. Palivizumab in preventing infection caused by respiratory syncitial virus (RSV). Rev. chil. pediatr. [online]. 2002, vol.73, n.1, pp.9-14. ISSN 0370-4106. http://dx.doi.org/10.4067/S0370-41062002000100003.
Palivizumab (P) is a specific monoclonal antibody directed against RSV and has been shown to be effective in decreasing hospitalization for RSV caused infections in very low weight babies (VLBM). Objective: to evaluate its effectiveness and safety in a cohort of Chilean VLBW infants during winter, when the incidence of RSV infections is highest. Patient and Methods: 61 infants of less than 34 weeks of gestional age and born between mat and september 1999 and 2000 were allocated to receive P (15 mg/kg im). We obtained informed parental consent in 44 (72.1%) to procede, the other 17 whose parents refused were used as controls. A group of similar characteristics (n= 75) born during the same period in 1997 and 1998 were used as historical controls. Results: 28 infants (37.3%) of the historical control group were hospitalized, 46.4% with RSV, as were 3 of the 17 who refused P. In those taking P none were admitted with RSV infection. Neither adverse effects due to P or mortality associated with RSV were recorded. Conclusions: P is safe and useful in decreasing the admission rate in preterm infants, and is in agreement with other published trials. Its impact on mortality will need larger multicentre studies. These results suggest there is a cost-benefit advantage of using P, and to consider incorporating its use in the public health system. In private medicine this information must be given to parents as an ethical issue
Palabras clave : premature infants; RSV; prophylaxis; hospitalization.